What's in Teva Branded Pharmaceutical Products R&D, Inc.'s pipeline?

Teva Branded Pharmaceutical Products R&D, Inc. has 82 drugs in our index: 17 marketed, 0 filed, 34 in Phase 3, 15 in Phase 2, 15 in Phase 1.

Which companies overlap with Teva Branded Pharmaceutical Products R&D, Inc.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, Organon and Co, AstraZeneca, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/teva-branded-pharmaceutical-products-r-d-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Teva Branded Pharmaceutical Products R&D, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teva Branded Pharmaceutical Products R&D, Inc. pipeline: 17 marketed, 0 filed, 34 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

17 marketed 0 filed 34 Phase 3 15 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Albuterol eMDPI DS	Albuterol eMDPI DS	marketed	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor	Respiratory
ProAir® HFA	ProAir® HFA	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor	Respiratory / Pulmonology
FLOVENT HFA	FLOVENT HFA	marketed
Albuterol-HFA-MDI	Albuterol-HFA-MDI	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor	Respiratory
Standard of Care Asthma Medication	Standard of Care Asthma Medication	marketed			Respiratory/Pulmonology
Glatiramer acetate (GA)	Glatiramer acetate (GA)	marketed	Immunomodulator; disease-modifying therapy (DMT)		Immunology; Neurology
ABS	ABS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2	Cardiovascular
Standard of Care Rescue Medication	Standard of Care Rescue Medication	marketed
Albuterol-HFA-BAI	Albuterol-HFA-BAI	marketed
Oral Corticosteroid (OCS)	Oral Corticosteroid (OCS)	marketed	Glucocorticoid	Glucocorticoid receptor	Immunology
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase	Oncology; Neurology; Cardiology
Servent Diskus	Servent Diskus	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor	Respiratory / Pulmonology

Therapeutic area mix

Respiratory · 11
Respiratory / Pulmonology · 6
Respiratory/Pulmonology · 5
Immunology; Neurology · 3
Contraception / Gynecology · 3
Cardiovascular · 2
Immunology · 2
Immunology / Rheumatology / General anti-inflammatory · 1
Oncology; Neurology; Cardiology · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 15 shared drug classes
Sanofi · 9 shared drug classes
Organon and Co · 9 shared drug classes
AstraZeneca · 9 shared drug classes
Pfizer · 7 shared drug classes
Hoffmann-La Roche · 5 shared drug classes
Chiesi Farmaceutici S.p.A. · 5 shared drug classes
Sumitomo Pharma America, Inc. · 5 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Teva Branded Pharmaceutical Products R&D, Inc.:

Cite this brief

Drug Landscape (2026). Teva Branded Pharmaceutical Products R&D, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/teva-branded-pharmaceutical-products-r-d-inc. Accessed 2026-05-16.